強
強気
強気 · 25%VSA
$1.95
シナリオ価格
$2.350
+1.236 (+52.60%)終値時点
Loading chart…
- 高値
- 2.350
- 始値
- 1.990
- 出来高加重平均価格
- 2.17
- 出来高
- 29.80M
- 時価総額
- —
- 安値
- 1.800
- 売買代金
- 64.57M
- EV/EBITDA（TTM）
- 0.00
VisionSys AI Inc is a holding company primarily engaged in the development of brain-computer interface (BCI) technologies and related businesses. The Company's main business is developing, procuring, selling, and distributing BCI-enabled or BCI-adjacent products and solutions, and to provide related technical services. The BCI technologies are used in medical and healthcare-related applications, including functional rehabilitation, communication support, neurological disease-related monitoring and intervention, sensory assistance, and general wellness management. The Company mainly operates its businesses in the domestic market.
AI分析 of VisionSys AI Inc (VSA)
売りGiven the current price of $1.62, the stock has dropped 93.41% year-to-date and is trading near its 52-week low of $1.56. The RSI is at 28.371, indicating that the stock is oversold, but the forward P/E ratio of 23.4742 suggests high future earnings expectations that may not be met, especially with a significant projected net margin loss of -3853.03% in Q4 2025. The main risk is the company's extremely low current ratio of 0.05, indicating potential liquidity issues.
バリュエーション指標
VisionSys AI Inc（VSA）の現在の予想PERは23.47で、5年平均は8.69です。
Alphio AI による VSA の価格シナリオ
シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト（25 / 50 / 25）であり、保証ではありません。
イベントタイムライン
ニュース
8.505-05seekingalphaVisionSys AI Announces 1-for-10 ADS Reverse Split Plan
- 8.505-05seekingalpha
VisionSys AI Announces Reverse ADS Split Plan
8.503-27NewsfilterVisionSys AI Inc. Secures $3 Million in Direct Offering
9.503-12BenzingaPetco Reports Strong Q4 Results, Shares Surge
8.512-18GlobenewswireVisionSys AI Inc (VSA) Executes 1-for-50 Reverse Stock Split, Reducing Shares to Approximately 554 Million
VSA のよくある質問 — Alphio AI が回答
VisionSys AI Inc is a holding company primarily engaged in the development of brain-computer interface (BCI) technologies and related businesses. The Company's main business is developing, procuring, selling, and distributing BCI-enabled or BCI-adjacent products and solutions, and to provide related technical services. The BCI technologies are used in medical and healthcare-related applications, including functional rehabilitation, communication support, neurological disease-related monitoring and intervention, sensory assistance, and general wellness management. The Company mainly operates its businesses in the domestic market. It operates in the Healthcare sector.
Given the current price of $1.62, the stock has dropped 93.41% year-to-date and is trading near its 52-week low of $1.56. The RSI is at 28.371, indicating that the stock is oversold, but the forward P/E ratio of 23.4742 suggests high future earnings expectations that may not be met, especially with a significant projected net margin loss of -3853.03% in Q4 2025. The main risk is the company's extremely low current ratio of 0.05, indicating potential liquidity issues.
コミュニティ
もっと見る ↗投稿はまだありません
登録またはログインして議論に参加関連記事
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。